Sionna Therapeutics, Inc. (SION)
| Market Cap | 2.00B +259.1% |
| Revenue (ttm) | n/a |
| Net Income | -75.27M |
| EPS | -1.88 |
| Shares Out | 45.14M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 405,313 |
| Open | 43.93 |
| Previous Close | 43.31 |
| Day's Range | 43.36 - 45.10 |
| 52-Week Range | 11.77 - 46.46 |
| Beta | n/a |
| Analysts | Strong Buy |
| Price Target | 50.44 (+14.04%) |
| Earnings Date | May 22, 2026 |
About SION
Sionna Therapeutics, Inc., a clinical-stage biopharmaceutical company, researches and develops medicines for the treatment of cystic fibrosis (CF). It develops galicaftor (SION-2222), a transmembrane domain 1 (TMD1)-directed cystic fibrosis transmembrane conductance regulator (CFTR) that has completed Phase 2 trial; navocaftor (SION-3067), a potentiator that has completed Phase 2 trial; SION-109, an intracellular loop 4 directed CFTR corrector that has completed Phase 1 trial; SION-2851, a TMD1-directed CFTR corrector that has completed Phase 1... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 9 analysts, the average rating for SION stock is "Strong Buy." The 12-month stock price target is $50.44, which is an increase of 14.04% from the latest price.
News
Sionna Therapeutics initiated with an Outperform at Wedbush
Wedbush analyst Laura Chico initiated coverage of Sionna Therapeutics (SION) with an Outperform rating and $53 price target The company’s focus remains on developing next-generation CFTR modulators th...
Sionna Therapeutics price target raised to $63 from $52 at JonesResearch
JonesResearch raised the firm’s price target on Sionna Therapeutics (SION) to $63 from $52 and keeps a Buy rating on the shares after the company completed enrollment in the Phase
Sionna Therapeutics Completes Enrollment in PreciSION CF Phase 2a Trial Evaluating NBD1 Stabilizer, SION-719, Added to Standard of Care in Participants with Cystic Fibrosis
Topline data is on track for anticipated readout in the summer of 2026 Topline data is on track for anticipated readout in the summer of 2026
Sionna Therapeutics to Participate in the Raymond James 2026 Biotech Innovation Symposium
WALTHAM, Mass., April 07, 2026 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (Nasdaq: SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for...
Three new option listings on March 17th
New option listings for March 17th include GBank Financial Holdings Inc (GBFH), Oculis Holding AG (OCS), and Sionna Therapeutics Inc (SION).
Sionna Therapeutics Transcript: Leerink Global Healthcare Conference 2026
The company is advancing two NBD1 stabilizers for cystic fibrosis, targeting significant unmet need with both add-on and dual combination strategies. Key clinical data from ongoing studies are expected by mid-2026, supported by strong financial resources and a validated predictive assay.
Sionna Therapeutics price target raised to $50 from $45 at Guggenheim
Guggenheim raised the firm’s price target on Sionna Therapeutics (SION) to $50 from $45 and keeps a Buy rating on the shares after the company announced FY25 earnings. The firm
Sionna Therapeutics Transcript: TD Cowen 46th Annual Health Care Conference
The discussion highlighted the strategy to address unmet needs in CF by developing NBD1 stabilizers, with a focus on dual combinations aiming for clinically meaningful improvements in CFTR function. The phase II study is designed for robust mechanistic proof, and future plans include dose-ranging and co-formulation.
Sionna Therapeutics files automatic mixed securities shelf
08:21 EST Sionna Therapeutics (SION) files automatic mixed securities shelf
Sionna Therapeutics files automatic mixed securities shelf
08:21 EST Sionna Therapeutics (SION) files automatic mixed securities shelf
Sionna Therapeutics files automatic mixed securities shelf
08:21 EST Sionna Therapeutics (SION) files automatic mixed securities shelf
Sionna Therapeutics reports Q4 EPS (46c), consensus (55c)
Cash, cash equivalents and marketable securities totaled$310.3 millionas of December 31, 2025. Sionna expects its current cash position to fund operations into 2028. “2025 was a remarkable and transfo...
Sionna Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results
Ongoing PreciSION CF Phase 2a proof-of-concept trial evaluating NBD1 stabilizer SION-719 as an add-on to standard of care in participants with cystic fibrosis is on track with topline data anticipated...
Sionna Therapeutics initiated with an Outperform at Citizens
Citizens initiated coverage of Sionna Therapeutics (SION) with an Outperform rating and $63 price target Sionna is developing “differentiated,” small molecule therapies that could normalize CFTR funct...
Sionna Therapeutics to Participate in Upcoming March 2026 Investor Conferences
WALTHAM, Mass., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (Nasdaq: SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for ...
Sionna Therapeutics Transcript: Guggenheim Securities Emerging Outlook: Biotech Summit 2026
The summit highlighted a novel approach to CF treatment using NBD1 stabilizers, with key phase 2a and dual combination studies targeting mid-2026 data. The company aims to address unmet needs in a growing $12–17 billion market, supported by strong financials.
Sionna Therapeutics to Present at the Guggenheim Securities Emerging Outlook: Biotech Summit 2026
WALTHAM, Mass., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (Nasdaq: SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for ...
Sionna Therapeutics Transcript: 44th Annual J.P. Morgan Healthcare Conference
Focused on NBD1 stabilization, the company is advancing two lead programs targeting the F508del mutation in CF, with pivotal data expected mid-2026. Both add-on and dual combination strategies aim to surpass current standards, addressing a $12B+ market and significant unmet need.
Sionna Therapeutics price target raised to $58 from $50 at BTIG
BTIG raised the firm’s price target on Sionna Therapeutics (SION) to $58 from $50 and keeps a Buy rating on the shares. The firm’s thesis considers the strength of Sionna’s
Sionna Therapeutics price target raised to $58 from $50 at BTIG
BTIG analyst Kambiz Yazdi raised the firm’s price target on Sionna Therapeutics (SION) to $58 from $50 and keeps a Buy rating on the shares. A central element of the
Sionna Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
WALTHAM, Mass., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (Nasdaq: SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for ...
Sionna Therapeutics initiated with an Outperform at LifeSci Capital
LifeSci Capital analyst Cory Jubinville initiated coverage of Sionna Therapeutics (SION) with an Outperform rating and $60 price target Sionna is a clinical-stage pharmaceutical company focused on the...
Sionna Therapeutics Transcript: Citi Annual Global Healthcare Conference 2025
A differentiated approach to cystic fibrosis targets the NBD1 domain with two main clinical strategies, aiming for superior efficacy and broad patient impact. Strong financials support development through 2028, with pivotal data expected in mid-2026 and a focus on maximizing patient access and commercial opportunity.
Sionna Therapeutics Transcript: Evercore ISI 8th Annual HealthCONx Conference
Significant clinical progress was made with NBD1 stabilizers, including phase I completions and the launch of key phase II and combination studies. The team aims to address unmet needs in CF by improving CFTR function and is confident in their assay's predictive power, with pivotal data expected in mid-2026.
Sionna downgraded to Underperform from Sector Perform at RBC Capital
RBC Capital downgraded Sionna Therapeutics (SION) to Underperform from Sector Perform with an unchanged price target of $24. The company is pursuing a novel approach in what could be a